Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Common Equity (2016 - 2025)

VYNE Therapeutics (VYNE) has disclosed Common Equity for 10 consecutive years, with $27.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 46.69% year-over-year to $27.8 million, compared with a TTM value of $27.8 million through Dec 2025, down 46.69%, and an annual FY2025 reading of $27.8 million, down 46.69% over the prior year.
  • Common Equity was $27.8 million for Q4 2025 at VYNE Therapeutics, down from $38.9 million in the prior quarter.
  • Across five years, Common Equity topped out at $92.9 million in Q1 2021 and bottomed at $11.5 million in Q3 2023.
  • Average Common Equity over 5 years is $51.5 million, with a median of $48.6 million recorded in 2021.
  • The sharpest move saw Common Equity tumbled 71.29% in 2023, then surged 452.26% in 2024.
  • Year by year, Common Equity stood at $48.6 million in 2021, then tumbled by 35.85% to $31.2 million in 2022, then skyrocketed by 184.39% to $88.7 million in 2023, then tumbled by 41.3% to $52.1 million in 2024, then plummeted by 46.69% to $27.8 million in 2025.
  • Business Quant data shows Common Equity for VYNE at $27.8 million in Q4 2025, $38.9 million in Q2 2025, and $44.1 million in Q1 2025.